# To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

> **NCT06429722** · PHASE2 · COMPLETED · sponsor: **Neumora Therapeutics, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Major Depressive Episode Associated With Bipolar II Disorder

## Interventions

- **DRUG:** NMRA-335140 80 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06429722
- **Lead sponsor:** Neumora Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-13
- **Primary completion:** 2025-04-09
- **Final completion:** 2025-05-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429722, "To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06429722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*